| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -33.3 | -21.7 |
| EPS (diluted, $ a share) | $-0.45 | $-0.29 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: NKTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Nkarta, Inc.: key numbers
- Share price
- $1.21Close, Nov 16
- Market cap
- $86.8M
- Shares outstanding
- 71.7MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Nkarta, Inc.
All →Nkarta Clinical Trial Data
Nkarta announced positive initial clinical data from its Ntrust program evaluating NKX019, an allogeneic CAR NK cell therapy, for myositis and systemic sclerosis. In the 4 billion cells per dose cohort, 83% of myositis patients achieved moderate or major responses, while 86% of systemic sclerosis patients achieved an rCRISS-25 response or greater. The therapy demonstrated a favorable safety profile with no cases of CRS, ICANS, or GvHD across 40 treated patients.
Nkarta Business Update
Nkarta announced it will host a webcast on November 9, 2026, to review initial clinical data from its Ntrust clinical program evaluating NKX019 in myositis and systemic sclerosis. The data is being presented at the American College of Rheumatology (ACR) Convergence 2026 conference. This filing serves as an announcement of the upcoming data presentation and webcast, but does not disclose the actual clinical results themselves.
Nkarta Financial Results
Nkarta, Inc. reported third quarter 2026 financial results, highlighting a net loss of $33.3 million and a cash position of $216.0 million. The company announced that initial clinical data for its NKX019 cell therapy in myositis and systemic sclerosis will be presented at the ACR Convergence 2026 conference in November. Management expects its current cash runway to fund operations into 2029.
- Term
- Q3 2026
“NKX019 is advancing in our two lead indications, myositis and systemic sclerosis. We’re delighted to have been selected to present our initial clinical data in two oral presentations and one poster presentation at ACR Convergence 2026 in Orlando. We believe that the safety profile of engineered CAR-NK cells could broaden cell therapy access to reach far more patients. With off-the-shelf availability and outpatient dosing at a growing network of community-based sites, our program is designed to deliver on that potential.”
Paul J. Hastings, Chief Executive Officer of Nkarta